COMMUNIQUÉS West-GlobeNewswire

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
24/09/2026
Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes ARCHER II is the First Pivotal Trial Designed to [...]
New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
24/09/2026
In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and modulated STAT3- [...]
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
24/09/2026
Fort Lee, NJ, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the [...]
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
24/09/2026
Late-breaking presentation will highlight Phase 2b clinical data for MAR001, a potential first-in-class antibody targeting ANGPTL4 designed to lower triglycerides and improve metabolic function SOUTH SAN FRANCISCO and [...]
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
24/09/2026
New pre-specified analyses from the randomized Phase 2 study will further characterize the clinical potential of ELI-002 7P (camupepimut) in adjuvant pancreatic cancer Findings are expected to inform a refined Phase 3 [...]
Primmune Therapeutics Announces Enrollment Milestone in Phase 2 INFLECTION–003 Study of Polvitolimod HCl in Neoadjuvant Melanoma
24/09/2026
SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Primmune Therapeutics , a biotech company harnessing the power of the innate and adaptive immune system, today announced the enrollment of the second patient in its Phase 2 [...]
Precision Neuroscience Closes Oversubscribed $250M Series D Led by Pershing Square Inc., the Ackman Oxman Institute, and a Leading Life Sciences Investment Fund
24/09/2026
The round brings Precision's total capital raised to $430 million and follows more than 100 patient procedures across 18 major medical institutions NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Precision Neuroscience [...]
Biolinq Shine™ Receives FDA 510(k) Clearance for Over-the-Counter Use
24/09/2026
First needle-free wearable that tracks glucose, activity and sleep in a single device SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Biolinq Incorporated , a pioneering developer of precision multi-analyte biosensors to [...]
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
24/09/2026
Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of Etripamil MONTREAL and CHARLOTTE, N.C., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. ( [...]
Cronos Hosts 2026 Investor Day
24/09/2026
TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is hosting its first Investor Day today, September 24, 2026, at its Cronos [...]
Claris Bio Establishes Corporate Headquarters in San Francisco
24/09/2026
Relocation positions Claris within a leading life sciences and biotech innovation hub as the company advances CSB-001 toward pivotal studies in limbal stem cell deficiency (LSCD) SAN FRANCISCO, Sept. 24, 2026 (GLOBE [...]
SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma
24/09/2026
New findings highlight the therapy’s ability to preferentially destroy MGMT-positive tumor cells, the specific population that survives standard treatments and drives disease recurrence. TAIPEI, Taiwan, Sept. 24, 2026 ( [...]
Boehringer Ingelheim and WHO Foundation launch global collaboration to close the gap in obesity and metabolic health
24/09/2026
Supporting obesity and metabolic health with a USD 5 million contribution from Boehringer Ingelheim over three years Collaboration will strengthen integrated care for obesity and related cardiovascular, kidney, liver [...]
IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
24/09/2026
2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory readout in OVATION 3 [...]
SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy
24/09/2026
Prestigious honor recognizes Dr. Humes’ pioneering work in developing the Selective Cytopheretic Device (SCD) therapy, commercialized by SeaStar Medical as QUELIMMUNE ® for critically ill pediatric patients with acute [...]
Free Family Fun Night in Cedar Park: Ally Medical ER Ribbon Cutting
24/09/2026
Ally Medical ER Cedar Park hosts an evening of free food, drinks, giveaways, and kid-friendly games on October 1st. CEDAR PARK, Texas, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ally Medical Emergency Room is bringing the Cedar [...]
HCW Biologics Announces Pricing of $1.5 Million Private Placement
24/09/2026
MIRAMAR, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to [...]
Applied Biologics Announces Publication of New XWRAP® Translational Research Demonstrating More Favorable Wound-Healing Biology
24/09/2026
Study shows approximately 74% higher integrated histology resolution score and substantial reductions in inflammation and residual tissue injury compared with conventionally processed placental tissue SCOTTSDALE, Ariz [...]
Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform
24/09/2026
European patent strengthens protection for proprietary autonomic nervous system assessment technologies, further expanding Company's international patent portfolio THE WOODLANDS, TX, Sept. 24, 2026 (GLOBE NEWSWIRE) -- [...]

Pages